Diabetes(Oral Hypoglycemic Agents)
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- Category
- Other Pharmaceutical Chemicals
Myungmoon Pharm. Co., Ltd.
- Country / Year Established
- South Korea /
- Business type
- Others
- Verified Certificate
-
16
Product name | Diabetes(Oral Hypoglycemic Agents) | Certification | - |
---|---|---|---|
Category | Other Pharmaceutical Chemicals | Ingredients | - |
Keyword | - | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | Stock | - | |
Supply type | - | HS code | - |
Product Information
Mepiril Tab.(Glimepiride 2mg) |
Composition : One tablet contains Indication & Usage : noninsulin-dependent (Type II) diabetes mellitus (NIDDM)
Dosage & Administration :
Package : 100, 500 Tablets |
Metiben Tab. 500/5mg(Metformin HCL 500mg, Glibenclamide 5mg) Metiben Tab. 500/2.5mg(Metformin HCL 500mg, Glibenclamide 2.5mg) |
Composition : One tablet contains Indication & Usage :
Dosage & Administration
Package : 4ml/Amp x 5,20ml/Amp x 5 |
Glyact Tab. 200mg(Piogliazone HCL 200mg) |
Composition : One tablet contains Indication & Usage : Dosage & Administration :
Package : 30 Tablets |
B2B Trade
Price (FOB) | Negotiable | transportation | - |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Negotiable | Shipping time | Negotiable |
- President
- LEE, GYU HUOK
- Address
- Myungmoon B/D, 946-18, Dokok-Dong, Gangnam-Ku, Korea
- Product Category
- Beauty & Personal Care,Chemical & Pharmaceutical Machinery,Pharmaceuticals
- No. of Total Employees
- 101-500
- Company introduction
-
In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation. Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.
Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and generalmedicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.
Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, however, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future. To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.
Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.
- Main Markets
-
China
- Main Product